MeiraGTx Holdings plc (MGTX)
The price, the headline numbers and the latest news, in one place.
MeiraGTx Holdings plc (MGTX) Stock Price, Analysis & Data
| Bid | 13.76 |
| Market Cap | 1.33B |
| Revenue (ttm) | 398M |
| Net Income (ttm) | 79M |
| 1.25 | |
| 0.87 | |
| 15.87 | |
| -9.94 | |
| P/B (ttm) | 6.03 |
| P/S (ttm) | 3.34 |
| Earnings Date | Nov 12, 2026 |
| Ask | 17.42 |
| Volume | 715,708 |
| Avg. Volume (20D) | 839,225 |
| Open | 13.67 |
| Previous Close | 13.82 |
| Day's Range | 13.55 - 14.01 |
| 52-Week Range | 6.62 - 15.35 |
| Analyst | Strong<br>Buy |
| Price Target | 27 (95.51%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About MGTX
MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xerostomia, as well as for Sjogren's syndrome; AAV-GA...
Financial Performance
In 2025, MeiraGTx s plc's revenue was 81.39M, an increase of 144.57% compared to the previous year's 33.28M. Earnings were -114.2M, a decrease of -22.73%.
Financial StatementsAnalyst Forecast
According to 7 analyst ratings, the average rating for MGTX stock is "Strong Buy". The 12-month stock price forecast is 27, which is upside of 95.51% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $293K misses estimates by $0, with -84.79% YoY decline.
- EPS of 2.52 exceeds estimates by 2.94, with 625.00% YoY growth.
Analysts project revenue of ... Upgrade
